Guardant Health: Leveraging Liquid Biopsy Testing Momentum

First Principles Partners1.77K FollowersFollow5ShareSavePlay(10min)CommentsSummaryGuardant Health, Inc. maintains a bullish outlook, driven by strong oncology segment growth and leadership in liquid biopsy testing.GH delivered FY2025 revenue of $982 million, up 33% YoY, with oncology contributing 67.6% of total revenues and 26% YoY growth.Liquid biopsy adoption is accelerating, offering non-invasive cancer diagnostics and supporting GH’s revenue momentum and market outperformance.Despite sustained operating losses, GH is positioned for continued top-line growth, with FY2026 revenue estimated at $1.27 billion and a potential price target of $109.57. anamejia18/iStock via Getty Images Investment Thesis and Introduction We are in the 2nd quarter of the year 2026, and you notice that in my previous article, my rating for Guardant Health, Inc. (GH) was bullish, drivenThis article was written byFirst Principles Partners1.77K FollowersFollowFirst Principles Partners is an equity research analyst specializing in technology, innovation, and sustainability investment. My unique approach, "First Principles," involves breaking down complex problems to their most basic elements in terms of financial and technology, enabling me to uncover overlooked investment opportunities.With a strong background in investment, private equity and venture capital, I have a proven track record of delivering strong returns for readers. Articles on Seeking Alpha focus on emerging technologies, sustainable investing, and the intersection of innovation and finance. I am passionate about sharing insights with a wider audience and learning from fellow investors. Together, we can drive positive change and contribute to a more sustainable and innovative world.Analyst’s Disclosure: I/we have a beneficial long position in the shares of GH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.